FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Teva's Accupril gets FDA OK; Elder Pharmaceuticals buys Biomeda;

Tools

> Teva has nabbed an OK from the FDA for its generic form of Accupril, Pfizer's high blood pressure remedy. Total U.S. sales of the drug--branded and generic forms--amounted to $150 million for the 12 months ended June 30. Release

> Indian drug maker Elder Pharmaceuticals has agreed to buy Bulgaria's Biomeda Group for €10 million in cash. It's Elder's second acquisition in two months; the company hopes to use Biomeda as leverage for more European product launches. Report

> Medical laser-maker Candela got a new indication from the FDA for its Serenity device, used to reduce pain during pulsed-light and laser treatments. Report

And Finally... Low-dose products for menopause treatment have flooded the market with since the Women's Health Initiative found that hormone therapy could be harmful. But there's no research proving low doses are safer than traditional products. Article

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Teva Pharmaceutical   Pfizer   FDA   Elder Pharmaceuticals   Candela   Bimeda Groups   Accupril  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.